| [1] |
Razumilava N, Gores GJ. Cholangiocarcinoma[J]. Lancet, 2014, 383(9935):2168-2179.
|
| [2] |
Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma[J]. HPB, 2008, 10(2):77-82.
|
| [3] |
Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise[J]. Oncologist, 2016, 21(5):594-599.
|
| [4] |
Shaib Y, EI-Serag HB. The epidemiology of cholangiocarcinoma[J]. Semin Liver Dis, 2004, 24(2):115-125.
|
| [5] |
Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? a meta-analysis of risk factors for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2012, 57(1):69-76.
|
| [6] |
Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60(6):1268-1289.
|
| [7] |
DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution[J]. Ann Surg, 2007, 245(5):755-762.
|
| [8] |
Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection[J]. Ann Surg, 2008, 248(1):84-96.
|
| [9] |
Li YY, Li H, Lv P, et al. Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment[J]. J Gastrointest Surg, 2011, 15(4):608-613.
|
| [10] |
Ma KW, Chok KSH, She WH, et al. Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? a propensity score-matched analysis[J]. Hepatol Int, 2018, 12(2):167-173.
|
| [11] |
Bergquist JR, Groeschl RT, Ivanics T, et al. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics[J]. HPB, 2016, 18(11):886-892.
|
| [12] |
Sapisochin G, Fidelman N, Roberts JP, et al. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma[J]. Liver Transpl, 2011, 17(8):934-942.
|
| [13] |
Facciuto ME, Singh MK, Lubezky N, et al. Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation[J]. Transplantation, 2015, 99(1):151-157.
|
| [14] |
Casavilla FA, Marsh JW, Iwatsuki S, et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma[J]. J Am Coll Surg, 1997, 185(5):429-436.
|
| [15] |
Takahashi K, Obeid J, Burmeister CS, et al. Intrahepatic cholangiocarcinoma in the liver explant after liver transplantation: histological differentiation and prognosis[J]. Ann Transplant, 2016(21):208-215.
|
| [16] |
Hong JC, Petrowsky H, Kaldas FM, et al. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma[J]. J Am Coll Surg, 2011, 212(4):514-520.
|
| [17] |
Sapisochin G, Rodríguez de Lope C, Gastaca M, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?[J]. Am J Transplant, 2014, 14(3):660-667.
|
| [18] |
Fu BS, Zhang T, Li H, et al. The role of liver transplantation for intrahepatic cholangiocarcinoma: a single-center experience[J]. Eur Surg Res, 2011, 47(4):218-221.
|
| [19] |
Robles R, Figueras J, Turrión VS, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma[J]. Ann Surg, 2004, 239(2):265-271.
|
| [20] |
Shimoda M, Farmer DG, Colquhoun SD, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature[J]. Liver Transpl, 2001, 7(12): 1023-1033.
|
| [21] |
Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. a 12-year single center experience[J]. Ann Surg, 1997, 225(5):472-481.
|
| [22] |
Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64(4):1178-1188.
|
| [23] |
Lee DD, Croome KP, Musto KR, et al. Liver transplantation for intrahepatic cholangiocarcinoma[J]. Liver Transpl, 2018, 24(5):634-644.
|
| [24] |
Jeong S, Tong Y, Sha M, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Oncotarget, 2017, 8(10):17292-17300.
|
| [25] |
Wang Q, Li J, Lei Z, et al. Prognosis of intrahepatic cholangiocarcinomas with HBV infection is better than those with hepatolithiasis after R0 liver resection: a propensity score matching analysis[J]. Ann Surg Oncol, 2017, 24(6):1579-1587.
|
| [26] |
Gupta R, Gupta J. Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation[J]. Hepatology, 2017, 65(5):1777-1778.
|
| [27] |
Kayhanian H, Smyth EC, Braconi C. Emerging molecular targets and therapy for cholangiocarcinoma[J]. World J Gastrointest Oncol, 2017, 9(7):268-280.
|
| [28] |
Rizvi S, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma[J]. J Hepatol, 2017, 67(3):632-644.
|
| [29] |
Al-Shamsi HO, Anand D, Shroff RT, et al. BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype[J].J Gastrointest Oncol, 2016, 7(4):556-561.
|
| [30] |
Zhu AX, Borger DR, Kim Y, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets[J]. Ann Surg Oncol, 2014, 21(12):3827-3834.
|
| [31] |
Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma[J]. Hepatology, 2014, 59(4):1427-1434.
|
| [32] |
Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology, 2013, 144(4):829-840.
|
| [33] |
Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma[J]. Cancer Discov, 2017, 7(10):1116-1135.
|
| [34] |
Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center[J]. Arch Surg, 2011, 146(6):683-689.
|
| [35] |
Lunsford KE, Javle M, Heyne K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series[J]. Lancet Gastroenterol Hepatol, 2018, 3(5):337-348.
|
| [36] |
Labib PL, Davidson BR, Sharma RA, et al. Locoregional therapies in cholangiocarcinoma[J]. Hepat Oncol, 2017, 4(4):99-109.
|
| [37] |
Sandler KA, Veruttipong D, Agopian VG, et al. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma[J]. Adv Radiat Oncol, 2016, 1(4): 237-243.
|
| [38] |
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281.
|
| [39] |
Rayar M, Levi Sandri GB, Houssel-Debry P, et al. Multimodal therapy including Yttrium-90 radioembolization as a bridging therapy to liver transplantation for a huge and locally advanced intrahepatic cholangiocarcinoma[J]. J Gastrointestin Liver Dis, 2016, 25(3):401-404.
|
| [40] |
Capecitabine extends survival for biliary tract cancer[J]. Cancer Discov, 2017, 7(7):OF1.
|
| [41] |
El-Khoueiry AB, Rankin C, Siegel AB, et al. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma[J]. Br J Cancer, 2014, 110(4):882-887.
|
| [42] |
Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study[J]. Lancet Oncol, 2010, 11(1):48-54.
|
| [43] |
Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9):1003-1010.
|